Skip to main content
OpenTrials
Completed

NCT Number: NCT06357819

INSTI® HCV (Hepatitis C Virus) Antibody Self-Test Contrived Result Interpretation

The purpose of this Interpretation Assessment was to document if "lay" people, non-professional and inexperienced in self-testing, were able to successfully perform the steps to use a Hepatitis C Virus (HCV) Self-Test (HCVST) device, without product familiarization [demonstration].

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

bioLytical Laboratories Inc.

Richmond, British Columbia, V6V 2A2, Canada

About this study

The intent of this study was to collect data regarding the result interpretation of contrived results of INSTI HCV ST. The contrived test devices refers to mock test devices pre-made by bioLytical Laboratories Inc. Each contrived/mock test device was assigned to an ID number to be randomly provided to the participants.

Primary Objectives were to document and record the following:

•Successful interpretation of contrived test results using mock test devices (strong positive, weak positive, negative and a range of invalid results).

Depending on the device being evaluated participants received a contrived INSTI® HCV Antibody Self Test membrane unit.

Participants were asked to interpret "mock" results [read contrived device results using the reference chart in the Instructions for Use (IFU)].

Participants were recruited from the Ezintsha Research Site which was a low-prevalence area and the Yeoville Harm Reduction Site which was a high-prevalence area in the city of Johannesburg in the Republic of South Africa. For the purposes of this assessment, the participant population was the general population. The participants did not have any experience in conducting any rapid diagnostic self-test using standard test kits, nor were they familiar with the prospective HCVST devices prior to entering into this mock result interpretation assessment.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Understands and sign the written informed Consent form
  • Able to complete the required testing on the allocated testing day[s]
  • Able to speak/read English
  • ≥18 years of age
  • Provide a level of education (minimum grade 7)

Exclusion criteria

  • Does not meet the inclusion criteria
  • A practicing medical healthcare professional [doctor, nurse or counsellor that performs testing with Rapid Tests]
  • Has used blood-based RDT for self-testing previously, either HIV or HCV
  • Any condition which, in the opinion of the facilitator, would make the participant unsuitable or unsafe for enrolment or could interfere with the completion of the mock result interpretation assessment, consent form and questionnaire etc. or bias the outcome

Treatment and study plan

INSTI HCV Self Test

Device

Each participant was provided with contrived INSTI membrane units by the study observer, in random order, and was asked to interpret the results using the INSTI HCV ST Instructions for Use.

Primary outcomes

  1. Successful Interpretation of contrived devices

    Time frame: 3 Months

Sponsors and collaborators

Lead sponsor

bioLytical Laboratories

Industry

Registry information

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
Apr 10, 2024
Registry last updated
Apr 10, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.